Connection

WEIYA XIA to Female

This is a "connection" page, showing publications WEIYA XIA has written about Female.
Connection Strength

0.158
  1. Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat. 2006 Aug; 98(3):295-301.
    View in: PubMed
    Score: 0.008
  2. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
    View in: PubMed
    Score: 0.006
  3. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun. 2021 05 13; 12(1):2788.
    View in: PubMed
    Score: 0.006
  4. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020 10; 22(10):1264-1275.
    View in: PubMed
    Score: 0.005
  5. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res. 1999 Dec; 5(12):4164-74.
    View in: PubMed
    Score: 0.005
  6. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
    View in: PubMed
    Score: 0.005
  7. Targeting PKCd as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell. 2018 12 10; 34(6):954-969.e4.
    View in: PubMed
    Score: 0.005
  8. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019 01; 29(1):83-86.
    View in: PubMed
    Score: 0.005
  9. Generation of an induced pluripotent stem cell line from an individual with a heterozygous RECQL4 mutation. Stem Cell Res. 2018 12; 33:36-40.
    View in: PubMed
    Score: 0.005
  10. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7.
    View in: PubMed
    Score: 0.005
  11. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018 08; 28(8):862-864.
    View in: PubMed
    Score: 0.005
  12. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. Cancer Res. 2018 07 15; 78(14):3761-3768.
    View in: PubMed
    Score: 0.005
  13. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018 05 15; 9(1):1908.
    View in: PubMed
    Score: 0.005
  14. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018 02 12; 33(2):187-201.e10.
    View in: PubMed
    Score: 0.004
  15. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515.
    View in: PubMed
    Score: 0.004
  16. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer. 2018 Jan; 25(1):74-80.
    View in: PubMed
    Score: 0.004
  17. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017 Jul 15; 23(14):3711-3720.
    View in: PubMed
    Score: 0.004
  18. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res. 1997 Jan; 3(1):3-9.
    View in: PubMed
    Score: 0.004
  19. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939.
    View in: PubMed
    Score: 0.004
  20. GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016 Aug 30; 7(35):57131-57144.
    View in: PubMed
    Score: 0.004
  21. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.004
  22. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016 Mar 15; 76(6):1451-62.
    View in: PubMed
    Score: 0.004
  23. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res. 2016 Mar 01; 76(5):1284-96.
    View in: PubMed
    Score: 0.004
  24. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal. 2014 Jul 29; 7(336):ra71.
    View in: PubMed
    Score: 0.004
  25. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res. 2013 Nov 01; 73(21):6516-25.
    View in: PubMed
    Score: 0.003
  26. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One. 2013; 8(9):e73406.
    View in: PubMed
    Score: 0.003
  27. Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix. Mol Carcinog. 2014 Dec; 53(12):1011-26.
    View in: PubMed
    Score: 0.003
  28. Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell. 2013 Jun 10; 23(6):796-810.
    View in: PubMed
    Score: 0.003
  29. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature. 2013 May 16; 497(7449):383-7.
    View in: PubMed
    Score: 0.003
  30. SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev. 2013 Feb 01; 27(3):274-87.
    View in: PubMed
    Score: 0.003
  31. Epithelial-mesenchymal transition induced by TNF-a requires NF-?B-mediated transcriptional upregulation of Twist1. Cancer Res. 2012 Mar 01; 72(5):1290-300.
    View in: PubMed
    Score: 0.003
  32. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug; 8(8):2375-82.
    View in: PubMed
    Score: 0.002
  33. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Ther. 2004 Sep; 11(9):594-602.
    View in: PubMed
    Score: 0.002
  34. Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression. Cancer Lett. 2001 Dec 28; 174(2):151-8.
    View in: PubMed
    Score: 0.001
  35. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene. 2001 Oct 18; 20(47):6960-4.
    View in: PubMed
    Score: 0.001
  36. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001 Sep; 3(9):802-8.
    View in: PubMed
    Score: 0.001
  37. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.
    View in: PubMed
    Score: 0.001
  38. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001 Mar; 3(3):245-52.
    View in: PubMed
    Score: 0.001
  39. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog. 2001 Mar; 30(3):169-75.
    View in: PubMed
    Score: 0.001
  40. [Immunologic reaction of cervical lymph nodes in relation to the prognosis of oral squamous cell carcinoma]. Zhonghua Kou Qiang Ke Za Zhi. 1980 Dec; 15(4):211-5.
    View in: PubMed
    Score: 0.001
  41. The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res. 2000 Sep 01; 60(17):4913-20.
    View in: PubMed
    Score: 0.001
  42. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res. 2000 Jun 15; 60(12):3123-6.
    View in: PubMed
    Score: 0.001
  43. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med. 2000 Feb; 6(2):189-95.
    View in: PubMed
    Score: 0.001
  44. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncol Rep. 1999 Mar-Apr; 6(2):257-62.
    View in: PubMed
    Score: 0.001
  45. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) J Natl Cancer Inst. 1997 Oct 15; 89(20):1524-9.
    View in: PubMed
    Score: 0.001
  46. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 1997 Feb 06; 14(5):561-8.
    View in: PubMed
    Score: 0.001
  47. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995 May 18; 10(10):1947-54.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.